Mucosal and Systemic Immune Responses Induced by Intranasal Immunization of Recombinant Bacillus Subtilis Expressing the P97R1, P46 Antigens of Mycoplasma Hyopneumoniae

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2019 Sep 8

PMID 31492763

Citations 7

Authors

Yongheng Wang

Jialu Wang

Mengyun Zhou

Peng Liu

En Zhang

Yuchen Li

Jian Lin

Zhixin Feng

Qian Yang

Affiliations

Soon will be listed here.

Abstract

Mycoplasma hyopneumoniae (M. hyopneumoniae) is the pathogen of swine enzootic pneumonia, a chronic respiratory disease affecting pigs of all ages. The ciliated epithelial cells of the respiratory tract are the main target invaded and colonized by M. hyopneumoniae. Therefore, the ideal vaccine would be mucosally administered and able to stimulate suitable mucosal immunity and prevent the adherence of pathogens to mucosal cell surfaces. Currently, Bacillus subtilis as a recombinant vaccine carrier has been used for antigen delivery and proved to be effectively enhancing the innate immunity of nasal mucosa. Here, our study attempts to construct recombinant Bacillus subtilis (B.S-P97R1, B.S-P46), which can express the P97R1 or P46 antigen of M. hyopneumoniae, and to evaluate the immune responses in BALB/c mice. Initially, we respectively successfully constructed recombinant B.S-P97R1, B.S-P46 and validated the expression of antigen proteins by Western analysis. Then, recombinant B.S-P97R1 or B.S-P46 were respectively intranasally (i.n.) immunized in mice. Both strong P97R1-specific and P46-specific immunoglobulin G (IgG), secretory immunoglobulin A (SIgA) antibodies were induced in sera, bronchoalveolar lavage fluids (BALs) by ELISA analysis. Moreover, the levels of specific IL-4, IFN-γ in the immunized mice were elevated, and the proliferation of lymphocytes was also enhanced. In general, intranasal inoculation of recombinant B.S-P97R1 or B.S-P46 resulted in strong mucosal immunity, cell-mediated and humoral immunity, which was a mixed Th1/Th2-type response. In addition, our results provided a potential novel strategy that may be applied to the development of vaccines against M. hyopneumoniae.

Citing Articles

The protein Mhp274 elicits mucosal and systemic immune responses in mice.

Xie M, Huang Z, Zhang Y, Gan Y, Li H, Li D Front Cell Infect Microbiol. 2025; 15:1516944.

PMID: 39991712 PMC: 11842358. DOI: 10.3389/fcimb.2025.1516944.

Important role of Bacillus subtilis as a probiotic and vaccine carrier in animal health maintenance.

Yuan C, Ji X, Zhang Y, Liu X, Ding L, Li J World J Microbiol Biotechnol. 2024; 40(9):268.

PMID: 39007987 DOI: 10.1007/s11274-024-04065-0.

Mechanisms and applications of probiotics in prevention and treatment of swine diseases.

Zhang Y, Zhang Y, Liu F, Mao Y, Zhang Y, Zeng H Porcine Health Manag. 2023; 9(1):5.

PMID: 36740713 PMC: 9901120. DOI: 10.1186/s40813-022-00295-6.

Oral Immunization with Attenuated Choleraesuis Expressing the P42 and P97 Antigens Protects Mice against Challenge.

Zhou G, Tian Y, Tian J, Ma Q, Huang S, Li Q Microbiol Spectr. 2022; 10(6):e0236122.

PMID: 36377878 PMC: 9769600. DOI: 10.1128/spectrum.02361-22.

Bacillus subtilis spores as delivery system for nasal Plasmodium falciparum circumsporozoite surface protein immunization in a murine model.

Almeida M, Alves K, de Vasconcelos M, Pinto T, Gloria J, Chaves Y Sci Rep. 2022; 12(1):1531.

PMID: 35087102 PMC: 8795416. DOI: 10.1038/s41598-022-05344-2.

References

Sisto F, Miluzio A, Leopardi O, Mirra M, Boelaert J, Taramelli D . Differential cytokine pattern in the spleens and livers of BALB/c mice infected with Penicillium marneffei: protective role of gamma interferon. Infect Immun. 2002; 71(1):465-73. PMC: 143270. DOI: 10.1128/IAI.71.1.465-473.2003. View

Shimoji Y, Oishi E, Muneta Y, Nosaka H, Mori Y . Vaccine efficacy of the attenuated Erysipelothrix rhusiopathiae YS-19 expressing a recombinant protein of Mycoplasma hyopneumoniae P97 adhesin against mycoplasmal pneumonia of swine. Vaccine. 2003; 21(5-6):532-7. DOI: 10.1016/s0264-410x(02)00462-0. View

Chen A, Fry S, Forbes-Faulkner J, Daggard G, Mukkur T . Comparative immunogenicity of M. hyopneumoniae NrdF encoded in different expression systems delivered orally via attenuated S. typhimurium aroA in mice. Vet Microbiol. 2006; 114(3-4):252-9. DOI: 10.1016/j.vetmic.2005.12.009. View

Ni J, Bi S, Xu W, Zhang C, Lu Y, Zhai L . Improved immune response to an attenuated pseudorabies virus vaccine by ginseng stem-leaf saponins (GSLS) in combination with thimerosal (TS). Antiviral Res. 2016; 132:92-8. DOI: 10.1016/j.antiviral.2016.05.018. View

Virginio V, Gonchoroski T, Andrade Paes J, Schuck D, Zaha A, Bunselmeyer Ferreira H . Immune responses elicited by Mycoplasma hyopneumoniae recombinant antigens and DNA constructs with potential for use in vaccination against porcine enzootic pneumonia. Vaccine. 2014; 32(44):5832-8. DOI: 10.1016/j.vaccine.2014.08.008. View

Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F . Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol. 2007; 126(4):297-309. PMC: 7130725. DOI: 10.1016/j.vetmic.2007.09.008. View

Vidarsson G, van der Pol W, van den Elsen J, Vile H, Jansen M, Duijs J . Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol. 2001; 166(10):6250-6. DOI: 10.4049/jimmunol.166.10.6250. View

Marchioro S, Simionatto S, Galli V, Conceicao F, Brum C, Fisch A . Production and characterization of recombinant transmembrane proteins from Mycoplasma hyopneumoniae. Vet Microbiol. 2011; 155(1):44-52. DOI: 10.1016/j.vetmic.2011.08.001. View

Wang J, Huang L, Mou C, Zhang E, Wang Y, Cao Y . Mucosal immune responses induced by oral administration recombinant expressing the COE antigen of PEDV in newborn piglets. Biosci Rep. 2019; 39(3). PMC: 6418403. DOI: 10.1042/BSR20182028. View

10.

Chen C, Wu S, Tjia W, Wang C, Lohka M, Wong S . Development of a LytE-based high-density surface display system in Bacillus subtilis. Microb Biotechnol. 2011; 1(2):177-90. PMC: 3864451. DOI: 10.1111/j.1751-7915.2007.00017.x. View

11.

Marchioro S, Sacristan R, Michiels A, Haesebrouck F, Conceicao F, Dellagostin O . Immune responses of a chimaeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs. Vaccine. 2014; 32(36):4689-94. DOI: 10.1016/j.vaccine.2014.05.072. View

12.

Conceicao F, Moreira A, Dellagostin O . A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice. Vaccine. 2006; 24(29-30):5734-43. DOI: 10.1016/j.vaccine.2006.04.036. View

13.

Wang X, Wang L, Huang X, Ma S, Yu M, Shi W . Oral Delivery of Probiotics Expressing Dendritic Cell-Targeting Peptide Fused with Porcine Epidemic Diarrhea Virus COE Antigen: A Promising Vaccine Strategy against PEDV. Viruses. 2017; 9(11). PMC: 5707519. DOI: 10.3390/v9110312. View

14.

van der Pol W, Vidarsson G, Vile H, van de Winkel J, Rodriguez M . Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). J Infect Dis. 2000; 182(4):1139-45. DOI: 10.1086/315825. View

15.

Yang Y, Jing Y, Yang J, Yang Q . Effects of intranasal administration with on immune cells in the nasal mucosa and tonsils of piglets. Exp Ther Med. 2018; 15(6):5189-5198. PMC: 5958783. DOI: 10.3892/etm.2018.6093. View

16.

Vranckx K, Maes D, Marchioro S, Villarreal I, Chiers K, Pasmans F . Vaccination reduces macrophage infiltration in bronchus-associated lymphoid tissue in pigs infected with a highly virulent Mycoplasma hyopneumoniae strain. BMC Vet Res. 2012; 8:24. PMC: 3349615. DOI: 10.1186/1746-6148-8-24. View

17.

Chen A, Fry S, Daggard G, Mukkur T . Evaluation of immune response to recombinant potential protective antigens of Mycoplasma hyopneumoniae delivered as cocktail DNA and/or recombinant protein vaccines in mice. Vaccine. 2008; 26(34):4372-8. DOI: 10.1016/j.vaccine.2008.06.005. View

18.

Galli V, Simionatto S, Marchioro S, Fisch A, Gomes C, Conceicao F . Immunisation of mice with Mycoplasma hyopneumoniae antigens P37, P42, P46 and P95 delivered as recombinant subunit or DNA vaccines. Vaccine. 2012; 31(1):135-40. DOI: 10.1016/j.vaccine.2012.10.088. View

19.

Sheldrake R, Romalis L, Saunders M . Serum and mucosal antibody responses against Mycoplasma hyopneumoniae following intraperitoneal vaccination and challenge of pigs with M hyopneumoniae. Res Vet Sci. 1993; 55(3):371-6. DOI: 10.1016/0034-5288(93)90110-2. View

20.

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View